Enanta Pharmaceuticals, Inc.
General ticker "ENTA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $156.7M (TTM average)
Enanta Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 46.9%.
Estimated limits based on current volatility of 2.0%: low 13.99$, high 14.56$
Factors to consider:
- Total employees count: 145 as of 2023
- Top business risk factors: Insufficient funding, Manufacturing disruptions, Labor/talent shortage/retention, Strategic risks and growth management, Intellectual property risks
- Price in estimated range
- Earnings for 9 months up through Q3 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-09-30 to 2026-09-30
- 2024-09-30 to 2025-09-30 estimated range: [6.53$, 16.49$]
- 2025-09-30 to 2026-09-30 estimated range: [6.85$, 16.92$]
Financial Metrics affecting the ENTA estimates:
- Negative: with PPE of -2.0 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -34.13 <= 0.33
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Positive: 18.93 < Shareholder equity ratio, % of 34.20 <= 41.86
- Positive: Investing cash flow per share per price, % of 25.24 > -0.66
- Negative: negative Industry operating income (median)
Short-term ENTA quotes
Long-term ENTA plot with estimates
Financial data
| YTD | 2022-09-30 | 2023-09-30 | 2024-09-30 |
|---|---|---|---|
| Operating Revenue | $86.16MM | $79.20MM | $67.64MM |
| Operating Expenses | $210.00MM | $216.41MM | $189.33MM |
| Operating Income | $-123.84MM | $-137.21MM | $-121.69MM |
| Non-Operating Income | $1.66MM | $6.21MM | $3.90MM |
| Interest Expense | $0.00MM | $5.15MM | $10.94MM |
| R&D Expense | $164.52MM | $163.52MM | $131.48MM |
| Income(Loss) | $-122.19MM | $-131.00MM | $-117.79MM |
| Taxes | $-0.43MM | $2.82MM | $-1.74MM |
| Profit(Loss)* | $-121.75MM | $-133.82MM | $-116.05MM |
| Stockholders Equity | $321.33MM | $216.74MM | $128.81MM |
| Assets | $375.41MM | $462.27MM | $376.65MM |
| Operating Cash Flow | $-84.78MM | $-103.15MM | $-78.76MM |
| Capital expenditure | $2.12MM | $9.06MM | $17.95MM |
| Investing Cash Flow | $54.90MM | $-53.58MM | $58.23MM |
| Financing Cash Flow | $20.03MM | $198.13MM | $-27.63MM |
| Earnings Per Share** | $-5.91 | $-6.38 | $-5.48 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.